Reaction
Cutaneous Lupus Erythematosus reporting signals
As of the last recalculation, Cutaneous Lupus Erythematosus appears in 1,935 FAERS reports alongside 32 co-occurring drug terms. The strongest observed disproportionality signal is TERBINAFINE HYDROCHLORIDE (PRR 41.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Terbinafine Hydrochloride | 34 | 41.9 | 42.0 |
| Nebivolol | 32 | 22.0 | 22.0 |
| Daspone | 15 | 16.7 | 16.7 |
| Dapsone Gel, 5% | 15 | 16.7 | 16.7 |
| Belimumab | 44 | 15.3 | 15.3 |
| Dapsone | 15 | 15.2 | 15.2 |
| Hydroxychloroquine | 86 | 12.9 | 12.9 |
| Clobetasol Propionate Ointment Usp, 0.05% | 10 | 10.5 | 10.5 |
| Clobetasol Propionate | 10 | 10.5 | 10.5 |
| Nebivolol Hydrochloride | 32 | 10.4 | 10.4 |
| Hydroxychloroquine Sulfate | 80 | 9.8 | 9.8 |
| Isosorbide Mononitrate | 17 | 8.9 | 8.9 |
| Isosorbide Dinitrate | 16 | 8.9 | 8.9 |
| Fluorouracil Cream, 0.5% | 56 | 8.1 | 8.1 |
| Fluorouracil | 56 | 8.0 | 8.0 |
| Letrozole Tablets | 34 | 7.7 | 7.7 |
| Adalimumab-Fkjp | 32 | 7.5 | 7.5 |
| Leflunomide | 70 | 7.4 | 7.4 |
| Adalimumab-Aaty | 32 | 7.4 | 7.4 |
| Nevirapine | 6 | 7.2 | 7.2 |
| Adalimumab-Adaz | 34 | 7.0 | 7.0 |
| Letrozole | 38 | 6.7 | 6.8 |
| Pemetrexed Disodium | 23 | 6.6 | 6.6 |
| Miconazole Nitrate | 5 | 6.2 | 6.2 |
| Panitumumab | 8 | 5.5 | 5.5 |
| Oxaliplatin | 31 | 4.6 | 4.6 |
| Pertuzumab | 11 | 4.4 | 4.4 |
| Durvalumab | 8 | 4.2 | 4.2 |
| Pemetrexed | 8 | 4.0 | 4.0 |
| Osimertinib | 11 | 3.7 | 3.7 |
| Atezolizumab | 13 | 3.6 | 3.6 |
| Palbociclib | 25 | 2.8 | 2.8 |